- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA, FTC Need to Strengthen Biosimilar Efforts, AHIP Says
AHIP wants the FDA and FTC to streamline product approvals, clarify the regulations governing biosimilars, put a stop to attempts to discourage people from using biosimilars, and start educating providers and patients about the safety and efficacy of these products.
Although federal regulators have taken steps to push biosimilar development and circulation into higher gear, lots of things can be done to make this happen faster, a group representing health care payers said in an appeal to regulators.
“If these barriers to competition are not meaningfully addressed, the biosimilar marketplace could fail to deliver on its promise of lower costs and greater patient access to vital biologic treatments,” America’s Health Insurance Plans (AHIP) said in a letter to the FDA and the Federal Trade Commission (FTC).
The group said the FDA and FTC need to streamline product approvals, clarify the regulations governing biosimilars, put a stop to attempts to discourage people from using biosimilars, and start educating providers and patients about the safety and efficacy of these products.
The group also warned about anti-substitution laws being adopted by states. “These state-level requirements could limit patient access to drugs that are not clinically different yet cost less than their brand name counterparts,” AHIP said.
To read more of this story, visit CenterforBiosimilars.com.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD
October 30th 2024Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).
Read More
